BioMarin a Buy with a $28 Target

Tags: bmrn
7 Jan 4:24am
Posted by ZacksResearch
0 Comments
Read original blog entry

BioMarin Pharmaceutical Inc. (BMRN) develops enzyme therapies for serious chronic genetic disorders and other diseases. Its leading product, Aldurazyme, is used for treating the ultra-rare genetic disorder
mucopolysaccharidosis-I (MPS-I) while its second product, Naglazyme, is appoved for the treatment of MPS-VI.

Recently, the company received both FDA and EC approval for its third product, Kuvan, for the treatment of PKU. Strong product sales will drive the company to profitability in 2008 and beyond.

The company's clinical pipeline, too, remains impressive. As such, we maintain our Buy rating on the stock with a price target of $28.

Read the full analyst report on BMRN



Get real-time market insights and profitable stock recommendations from the team of analysts at Zacks Equity Research. See all today’s Analyst Blog entries on Zacks.com.

Comments

Back to top

Post comment

Back to top

Post a comment

Please login to post a comment

About

ZacksResearch

Zacks Investment Research is one of the most highly regarded firms in the investment industry. Our firm has long believed that that quantitative models (like the Zacks Rank) can predict stock prices more accurately than individual analysts. However we also recognize that models are most effective when they are employed by analysts who have deep fundamental knowledge of the company and its industry. Consequently Zacks Equity Research combines Zacks quantitative models with the insight provided by an experienced team of 50 analysts to create superior long term stock recommendations. Discover all their timely insight and recommendations daily on Zacks.com.

Recent Entries